Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04142424CT.gov A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| azd2693 (this asset) | AstraZeneca | P1 | CC · 47 |
| Liraglutide | Anders Fink-Jensen, MD, DMSci | P4 | A |
| Semaglutide | Nordsjaellands Hospital | P4 | A |
| Metformin | Jinnah Sindh Medical University | P4 | BBB |
| Tirzepatide | Washington University School of Medicine | P4 | BBB |
| Pravastatin | National Human Genome Research Institute (NHGRI) | P4 | BBB |
| Midazolam | Baskent University | P4 | BB |
| Retrovir | Kirby Institute | P4 | BB |
| Hydrochlorothiazide | Vanderbilt University Medical Center | P3 | BB |
+42 more in the Metabolic Disease cohort
Other indications for azd2693
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | P2 | BB · 64 |
| Liver Disorder | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. azd2693 in Metabolic Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azd2693-metabolic-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →